Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) CEO Abraham Ceesay sold 22,541 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $46.26, for a total transaction of $1,042,746.66. Following the transaction, the chief executive officer owned 515,066 shares of the company’s stock, valued at approximately $23,826,953.16. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Abraham Ceesay also recently made the following trade(s):
- On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58.
- On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total transaction of $93,063.10.
Rapport Therapeutics Stock Performance
Shares of NASDAQ:RAPP opened at $47.42 on Friday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -15.60 and a beta of 0.97. Rapport Therapeutics, Inc. has a 1-year low of $13.86 and a 1-year high of $49.50. The company has a 50 day moving average price of $40.89 and a 200 day moving average price of $35.28.
Analyst Ratings Changes
Several analysts have issued reports on RAPP shares. Leerink Partners started coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price objective on the stock. Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Friday, July 17th. HC Wainwright raised their price objective on shares of Rapport Therapeutics from $40.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, BTIG Research reiterated a “buy” rating and set a $65.00 price objective on shares of Rapport Therapeutics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Rapport Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $61.57.
Get Our Latest Stock Analysis on RAPP
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Jupiter Topco LLC bought a new stake in Rapport Therapeutics in the second quarter worth $574,000. ARCH Venture Management LLC bought a new position in Rapport Therapeutics during the second quarter valued at about $155,376,512,000. Legal & General Group Plc acquired a new stake in shares of Rapport Therapeutics in the second quarter worth about $940,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Rapport Therapeutics in the second quarter worth about $2,904,000. Finally, Algert Global LLC bought a new stake in shares of Rapport Therapeutics during the 2nd quarter worth about $9,327,000.
Rapport Therapeutics Company Profile
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
- Five stocks we like better than Rapport Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
